Crinetics Pharmaceuticals, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 95/100
What the filing says
On July 6, 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $85.00 per share in cash, totaling ~$10.0B equity value (~$8.8B net of cash). The transaction was unanimously approved by both boards and is expected to close in Q3 2026, subject to regulatory approval and Crinetics stockholder approval. Q2 2026 net product revenue was $24.0M (vs. $0M in Q2 2025), with 245 enrollment forms submitted and 385 unique prescribers having dispensed PALSONIFY across three quarters of launch.
Why this rating
Acquisition at $10.0B (~3.7× current market cap of $2.7B) is transformational and definitively changes company trajectory. Deal materially rewards shareholders with premium valuation and exits market risk.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.